Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

ABSTRACT

Purpose: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.

Methods: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).

Results: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).

Conclusions: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.

KEYWORDS:

• Glioblastoma
• Neuro-Oncology
• Angiotensin receptor blockers
• Retrospective study
• Bevacizumab
• Pharmacoepidemiology

Additional information

Funding

The Danish Cancer Society (Kraeftens Bekaempelse ) supported this study under Grant R136-A8547. The Danish Cancer Society was not involved in the study design, data collection, analysis, data interpretation or manuscript writing.